• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings

    6/4/24 2:32:30 PM ET
    $ANNX
    $DBI
    $EQ
    $MLGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Get the next $ANNX alert in real time by email

    U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday.

    The Dow traded up 0.53% to 38,774.55 while the NASDAQ rose 0.29% to 16,877.87. The S&P 500 also rose, gaining, 0.25% to 5,296.54.

    Check This Out: Top 3 Financial Stocks You’ll Regret Missing This Quarter

    Leading and Lagging Sectors

    Real estate shares rose by 1.3% on Tuesday.

    In trading on Tuesday, materials shares fell by 1.4%.

    Top Headline

    Shares of Designer Brands Inc (NYSE:DBI) dipped more than 22% on Tuesday after the company reported worse-than-expected first-quarter earnings.

    The company reported first-quarter FY24 sales growth of 0.6% year-on-year to $746.596 million, beating the analyst consensus estimate of $741.630 million. Total comparable sales decreased by 2.5%. Adjusted EPS of 8 cents missed the analyst consensus estimate of 21 cents.

    Equities Trading UP
                           

    • MicroAlgo Inc (NASDAQ:MLGO) shares shot up 558% to $10.26 after the company announced that it will jointly establish a micro-consciousness quantum research center with WiMi.
    • Shares of Sobr Safe Inc (NASDAQ:SOBR) got a boost, surging 96% to $0.52 after the company announced SOBRsure device purchases from two new customers.
    • Annexon, Inc. (NASDAQ:ANNX) shares were also up, gaining 28% to $5.88 after the company’s Phase 3 trial of ANX005 met its primary endpoint.

    Equities Trading DOWN

    • ENDRA Life Sciences Inc (NASDAQ:NDRA) shares dropped 64% to $0.0788 after the company announced pricing of $8.0 million public offering.
    • Shares of Equillium Inc (NASDAQ:EQ) were down 24% to $1.12 after the company announced topline data from its Phase 2 study of EQ101 in alopecia areata.
    • Designer Brands Inc (NYSE:DBI) was down, falling 22% to $8.56 following first-quarter earnings.

    Also Check This Out: Wall Street’s Most Accurate Analysts’ Views On 3 Utilities Stocks With Over 4% Dividend Yields

    Commodities

    In commodity news, oil traded down 1% to $73.46 while gold traded down 0.9% at $2,348.30.

    Silver traded down 3.6% to $29.68 on Tuesday, while copper fell 2.7% to $4.5395.

    Euro zone

    European shares closed lower today. The eurozone's STOXX 600 fell 0.54%, Germany's DAX dipped 1.09% and France's CAC 40 fell 0.75%. Spain's IBEX 35 Index declined 0.97%, while London's FTSE 100 fell 0.37%.

    German jobless rate came in unchanged at 5.9% for the sixth straight month in May. Retail sales in the UK gained 0.4% from a year ago in May following a 4.4% decline in the prior month.

    Asia Pacific Markets

    Asian markets closed mixed on Tuesday, with Japan's Nikkei falling 0.22%, China's Composite Index gaining 0.14%, Hong Kong's Hang Seng Index climbing 0.22% and India's S&P BSE Sensex dipping 5.74%.

    Australia reported a current account deficit of AUD 4.9 billion in the first quarter, versus a revised surplus of AUD 2.7 billion in the fourth quarter. Retail sales in Australia increased by 0.1% month-over-month in April compared to a 0.4% decline in the previous period.

    Economics

    • The Logistics Manager's Index rose to 55.6 in May from a reading of 52.9 in April.
    • The RealClearMarkets/TIPP Economic Optimism Index declined to 40.5 in June compared to 41.8 in May.
    • U.S. factory orders increased by 0.7% from the prior month to $588.2 billion in April.
    • The number of job openings fell by 296,000 from the prior month to 8.059 million for April.

    Now Read This: Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

    Get the next $ANNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX
    $DBI
    $EQ
    $MLGO

    CompanyDatePrice TargetRatingAnalyst
    Equillium Inc.
    $EQ
    2/25/2026$5.00Buy
    Stifel
    Annexon Inc.
    $ANNX
    12/23/2025$16.00Buy
    Chardan Capital Markets
    Designer Brands Inc.
    $DBI
    6/11/2025$5.00 → $4.00Market Perform
    Telsey Advisory Group
    Equillium Inc.
    $EQ
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    Designer Brands Inc.
    $DBI
    3/21/2025$6.00 → $5.00Market Perform
    Telsey Advisory Group
    Designer Brands Inc.
    $DBI
    9/12/2024$10.00 → $6.00Market Perform
    Telsey Advisory Group
    Designer Brands Inc.
    $DBI
    6/5/2024$11.00 → $10.00Market Perform
    Telsey Advisory Group
    Annexon Inc.
    $ANNX
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $ANNX
    $DBI
    $EQ
    $MLGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Equillium with a new price target

    Stifel initiated coverage of Equillium with a rating of Buy and set a new price target of $5.00

    2/25/26 7:52:10 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Annexon with a new price target

    Chardan Capital Markets initiated coverage of Annexon with a rating of Buy and set a new price target of $16.00

    12/23/25 8:41:58 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telsey Advisory Group reiterated coverage on Designer Brands with a new price target

    Telsey Advisory Group reiterated coverage of Designer Brands with a rating of Market Perform and set a new price target of $4.00 from $5.00 previously

    6/11/25 8:21:14 AM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ANNX
    $DBI
    $EQ
    $MLGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP;Pres DesignerBrands Canada Turner Mary covered exercise/tax liability with 13,224 units of Class A Common Shares and converted options into 24,703 units of Class A Common Shares, increasing direct ownership by 72% to 27,318 units (SEC Form 4)

    4 - Designer Brands Inc. (0001319947) (Issuer)

    3/4/26 5:51:58 PM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    EVP & Brands President O'Donnell Andrea covered exercise/tax liability with 19,428 units of Class A Common Shares and converted options into 35,291 units of Class A Common Shares, increasing direct ownership by 41% to 54,904 units (SEC Form 4)

    4 - Designer Brands Inc. (0001319947) (Issuer)

    3/4/26 5:50:58 PM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    V. Chair; Ch Product Off Ferree Deborah L converted options into 35,291 units of Class A Common Shares and covered exercise/tax liability with 15,738 units of Class A Common Shares, increasing direct ownership by 6% to 326,243 units (SEC Form 4)

    4 - Designer Brands Inc. (0001319947) (Issuer)

    3/4/26 5:50:55 PM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $ANNX
    $DBI
    $EQ
    $MLGO
    SEC Filings

    View All

    Designer Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Designer Brands Inc. (0001319947) (Filer)

    3/4/26 4:30:47 PM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form 144 filed by Annexon Inc.

    144 - Annexon, Inc. (0001528115) (Subject)

    3/2/26 4:02:33 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by SOBR Safe Inc.

    S-8 - SOBR Safe, Inc. (0001425627) (Filer)

    2/27/26 5:14:59 PM ET
    $SOBR
    Newspapers/Magazines
    Consumer Discretionary

    $ANNX
    $DBI
    $EQ
    $MLGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Choi Jung bought $138,270 worth of shares (33,000 units at $4.19) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:20 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $DBI
    $EQ
    $MLGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

    Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad

    2/26/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference

    LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET. Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's lead therapeutic candidate is EQ504, a po

    2/25/26 8:30:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

    BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon

    2/24/26 8:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $DBI
    $EQ
    $MLGO
    Financials

    Live finance-specific insights

    View All

    Designer Brands Inc. Reports Third Quarter 2025 Financial Results

    Generated diluted earnings per share ("EPS") of $0.35 and adjusted diluted EPS of $0.38, both up over 40% compared to the same period last year Delivered 210-basis point improvement in gross margin over the same period last year Fiscal 2025 adjusted operating income expected to be in range of $50.0 million to $55.0 million COLUMBUS, Ohio, Dec. 9, 2025 /PRNewswire/ -- Designer Brands Inc. (NYSE: DBI) (the "Company," "we," "us," "our," and "Designer Brands"), one of the world's largest designers, producers, and retailers of footwear and accessories, today announced financial results for the third quarter ended November 1, 2025.

    12/9/25 6:45:00 AM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Designer Brands Inc. Announces Third Quarter 2025 Earnings Release Date

    COLUMBUS, Ohio, Nov. 18, 2025 /PRNewswire/ -- Designer Brands Inc. (NYSE:DBI), one of the world's largest designers, producers and retailers of footwear and accessories, announced the Company will issue its third quarter 2025 earnings on December 9, 2025. Management will host a conference call to discuss the results at 8:30 am E.T. A press release detailing the Company's results will be issued prior to the call. Investors and analysts interested in participating in the call are invited to dial 888-317-6003, or the international dial in, 412-317-6061, and reference conference I

    11/18/25 6:45:00 AM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potential to Be the First Approved Vision Sparing Therapy for the Treatment of Eight Million GA Patients Worldwide ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept Study Ongoing with Expected 2026

    11/10/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $DBI
    $EQ
    $MLGO
    Leadership Updates

    Live Leadership Updates

    View All

    Designer Brands Inc. Appoints Sheamus Toal as Chief Financial Officer

    Appointment Effective February 16, 2026 COLUMBUS, Ohio, Feb. 11, 2026 /PRNewswire/ -- Designer Brands Inc. (NYSE:DBI) (the "Company," "we," "us," "our," and "Designer Brands"), today announced that Sheamus Toal will join the company as Executive Vice President, Chief Financial Officer and Principal Financial Officer, effective February 16, 2026. Mark Haley, who has served as Interim Principal Financial Officer during the transition period, will return full time to his position as Senior Vice President, Controller and Principal Accounting Officer. Sheamus brings deep financial

    2/11/26 6:45:00 AM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million i

    8/14/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    $DBI
    $EQ
    $MLGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Designer Brands Inc.

    SC 13G/A - Designer Brands Inc. (0001319947) (Subject)

    12/12/24 6:00:14 PM ET
    $DBI
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care